Stock BIIB34 BIOGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Biogen Inc. Sao Paulo

Equities

BIIB34

BRBIIBBDR001

Market Closed - Sao Paulo
Other stock markets
 14:30:00 25/06/2024 BST 		5-day change 1st Jan Change
204.2 BRL +0.02% Intraday chart for Biogen Inc. +0.02% -0.47%
06-28 Biogen, Eisai Launch Leqembi in China to Treat Alzheimer's Disease MT
06-28 Eisai and Biogen launch Alzheimer's drug Leqembi in China RE

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)
PR
BIIB LAWSUIT ALERT: The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
PR
Biogen, Eisai Launch Leqembi in China to Treat Alzheimer's Disease
MT
Eisai and Biogen launch Alzheimer's drug Leqembi in China
RE
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
GL
Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China
CI
Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer
CI
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
PR
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen
PR
Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB
PR
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
PR
BIIB Investors Have Opportunity to lead Biogen Inc. Securities Fraud Lawsuit
PR
Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact The Gross Law Firm
PR
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
PR
TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
GL
Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP
PR
Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB
PR
BIIB Investors Have Opportunity to lead Biogen Inc. Securities Fraud Lawsuit
PR
Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB
PR
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIIB Stock
  4. BIIB34 Stock
  5. News Biogen Inc.